Structure-based virtual screening for low molecular weight chemical starting points for dipeptidyl peptidase IV inhibitors

被引:28
作者
Ward, RA
Perkins, TDJ
Stafford, J
机构
[1] AstraZeneca, Canc Discovery, Macclesfield SK10 4TG, Cheshire, England
[2] AstraZenecaR&D Molndal, S-43183 Molndal, Sweden
关键词
D O I
10.1021/jm0505866
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Structure-based virtual screening was performed against the target dipeptidyl peptidase IV (DPP-IV) to identify good chemical starting points for medicinal chemistry. A database of available compounds was filtered by calculated physical properties and undesired chemistry. This database was matched against two in-house designed DPP-IV pharmacophores, and the hits from these pharmacophore searches were docked into a DPP-IV crystal structure. Compounds were then selected for testing and 51 active compounds were identified from a list of 4000 compounds tested. These had activities ranging from 30% to 82% when tested at a concentration of 30 mu M in an enzyme inhibition assay.
引用
收藏
页码:6991 / 6996
页数:6
相关论文
共 34 条
[1]   Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes [J].
Ahrén, B ;
Landin-Olsson, M ;
Jansson, PA ;
Svensson, M ;
Holmes, D ;
Schweizer, A .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (05) :2078-2084
[2]   Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes [J].
Ahrén, B ;
Simonsson, E ;
Larsson, H ;
Landin-Olsson, M ;
Torgeirsson, H ;
Jansson, PA ;
Sandqvist, M ;
Båvenholm, P ;
Efendic, S ;
Eriksson, JW ;
Dickinson, S ;
Holmes, D .
DIABETES CARE, 2002, 25 (05) :869-875
[3]  
[Anonymous], MacroModel
[4]  
[Anonymous], Glide.
[5]   Comparison of automated docking programs as virtual screening tools [J].
Cummings, MD ;
DesJarlais, RL ;
Gibbs, AC ;
Mohan, V ;
Jaeger, EP .
JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (04) :962-976
[6]  
*DAYL CHEM INF SYS, SMILES, V471
[7]  
Daylight Chemical Information Systems Inc, DAYL FING
[8]   Inhibitors of dipeptidyl peptidase IV:: a novel approach for the prevention and treatment of Type 2 diabetes? [J].
Deacon, CF ;
Ahrén, B ;
Holst, JJ .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2004, 13 (09) :1091-1102
[9]   Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig [J].
Deacon, CF ;
Hughes, TE ;
Holst, JJ .
DIABETES, 1998, 47 (05) :764-769
[10]   Empirical scoring functions .1. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes [J].
Eldridge, MD ;
Murray, CW ;
Auton, TR ;
Paolini, GV ;
Mee, RP .
JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN, 1997, 11 (05) :425-445